IOSP
Innospec Inc.
NasdaqGSUSDEQUITY
Basic Materials
DELAYED
Last price
93.63
▲ 0.71 (0.76%)
MARKET · —
Price
Open
92.92
Prev close
92.92
Day high
93.88
Day low
92.76
Volume
114.32K
Market cap
$2.31B
P/E (TTM)
19.11
52W range
65.51 – 95.01
Trailing performance
Returnvs SPY
1W
-0.23%
+1.1%
1M
+11.34%
+7.6%
3M
+18.93%
+15.8%
6M
+15.28%
+4.2%
YTD
+22.33%
+10.0%
1Y
+11.93%
-8.1%
3Y
-10.05%
-84.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$2.31B
Enterprise value$2.11B
Revenue (TTM)$1.84B
Gross profit$505.90M
EBITDA$190.90M
Net income$121.50M
EPS (TTM)$4.90
Free cash flow$32.58M
Total cash$250.20M
Total debt$47.90M
Book value / share$54.54
Shares outstanding24.63M
Float24.32M
Short % of float2.57%
Dividend yield1.91%
Beta (5Y)0.91
Valuation & profitability ratios
Trailing P/E19.11
Forward P/E15.22
PEG ratio0.66
Price / sales—
Price / book1.72
EV / revenue1.15
EV / EBITDA11.06
Gross margin27.46%
Operating margin8.08%
Profit margin6.60%
Return on equity9.13%
Return on assets5.11%
Debt / equity3.55
Current ratio2.78
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $1.78B | $1.85B | $1.95B | $1.96B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $116.60M | $35.60M | $139.10M | $133.00M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $116.60M | $35.60M | $139.10M | $133.00M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.05 | 1.27 | +21.3% |
| Mar 2026 | 1.02 | 1.05 | +3.5% |
| Dec 2025 | 1.24 | 1.50 | +21.0% |
| Sep 2025 | 1.06 | 1.12 | +5.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.27 | 3 | $478.33M | +8.2% |
| Next quarter | 1.42 | 3 | $496.17M | +8.9% |
| Current year | 4.94 | 3 | $1.90B | +7.1% |
| Next year | 6.15 | 3 | $2.02B | +5.9% |
Analyst targets & ownership
Mean target$101.00
High target$110.00
Low target$93.00
Implied upside7.87%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy1 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders1.35%
Held by institutions102.09%
Institutions holding378
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+32.98K
Net buying
Buy transactions
13
44.63K shares
Sell transactions
13
11.65K shares
Net transactions
+26
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
332.27K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Mar 3, 26 | JONES DAVID BENTLEY General Counsel |
SELL | 1.03K | $77.76K | Direct |
| Feb 27, 26 | BLACKMORE MILTON C Director |
SELL | 594 | $45.47K | Direct |
| Feb 27, 26 | BLACKMORE MILTON C Director |
SELL | 594 | $45.47K | Direct |
| Feb 27, 26 | PADFIELD LAWRENCE J Director |
SELL | 594 | $45.47K | Direct |
| Feb 27, 26 | PADFIELD LAWRENCE J Director |
SELL | 594 | $45.47K | Direct |
| Feb 27, 26 | LANDLESS DAVID F Director |
SELL | 594 | $45.47K | Direct |
| Feb 27, 26 | LANDLESS DAVID F Director |
SELL | 594 | $45.47K | Direct |
| Feb 27, 26 | POCCIA CLAUDIA Director |
SELL | 119 | $9.11K | Direct |
| Feb 27, 26 | POCCIA CLAUDIA Director |
SELL | 119 | $9.11K | Direct |
| Feb 27, 26 | CLEMINSON IAN P Chief Financial Officer |
SELL | 2.38K | $182.21K | Direct |
| Feb 27, 26 | CLEMINSON IAN P Chief Financial Officer |
SELL | 2.38K | $182.20K | Direct |
| Feb 23, 26 | BLACKMORE MILTON C Director |
STOCK | 1.54K | $0 | Direct |
| Feb 23, 26 | PADFIELD LAWRENCE J Director |
STOCK | 1.54K | $0 | Direct |
| Feb 23, 26 | LANDLESS DAVID F Director |
STOCK | 1.54K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARNES CORBIN |
Officer | 13.24K | Stock Award(Grant) |
BLACKMORE MILTON C |
Director | 10.53K | Sale |
BOON PHILIP JOHN |
Officer | 20.08K | Stock Award(Grant) |
CLEMINSON IAN P |
Chief Financial Officer | 20.36K | Sale |
GRIFFIN HARDY LOUIS III |
Officer | 10.56K | Stock Award(Grant) |
JONES DAVID BENTLEY |
General Counsel | 14.69K | Sale |
LANDLESS DAVID F |
Director | 7.63K | Sale |
PADFIELD LAWRENCE J |
Director | 9.45K | Sale |
PARRETTE LESLIE J JR |
Director | 7.38K | Stock Award(Grant) |
WILLIAMS PATRICK S |
Chief Executive Officer | 239.50K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
93.54
+0.09% from price
SMA 20
90.60
+3.34% from price
SMA 50
86.11
+8.73% from price
SMA 100
82.03
+14.14% from price
SMA 200
79.49
+17.78% from price
EMA 12
92.48
+1.24% from price
EMA 26
89.96
+4.08% from price
EMA 50
87.06
+7.55% from price
RSI (14)
68.8
Neutral
MACD (12,26,9)
2.52
Hist -0.02
ATR (14)
2.25
2.40% of price
Realised vol 30D
22.2%
Annualised
Bollinger upper
97.77
20, 2σ
Bollinger lower
83.44
20, 2σ
50 / 200 cross
Golden
86.11 vs 79.49
Trend bias
Above 200
+17.78%
Risk profile
Beta vs SPY
0.55
Less volatile than market
Correlation to SPY
0.30
Largely independent
Realised vol 30D
22.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-25.5%
Peak to trough
Max drawdown 5Y
-49.9%
Peak to trough
ATR 14
2.25
2.40% of price
Beta (reported)
0.91
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.71
Call-heavy session
Put / call open interest
1.00
Positioning, not flow
Max pain
80.00
-14.6% from spot
ATM implied vol
1.6%
Nearest strike to spot
Skew (10% OTM)
+154.1%
Puts bid over calls
Call volume
7
Contracts, this expiry
Put volume
5
Contracts, this expiry
Heaviest call OI
80.00
10 contracts
Heaviest put OI
80.00
4 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Zacks Industry Outlook Highlights Air Products and Chemicals, DuPont de Nemours, Avient and Innospec
Zacks · 3d ago
4 Diversified Chemical Stocks to Gain Amid Stable End-market Demand
Zacks · 4d ago
Innospec (IOSP) Q2 2026 Earnings Call Transcript
Motley Fool · 10d ago
Is Innospec (IOSP) Still Undervalued After Its Q2 Earnings Beat?
Simply Wall St. · 14d ago
IOSP's Q2 Earnings Surpass Estimates on Broad-Based Growth
Zacks · 15d ago
Is Innospec (IOSP) Stock Outpacing Its Basic Materials Peers This Year?
Zacks · 15d ago
Innospec Inc (IOSP) (Q2 2026) Earnings Call Highlights: Strong Growth Across All Segments, but ...
GuruFocus.com · 17d ago
Innospec Q2 Earnings Call Highlights
MarketBeat · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.